Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Reiterated by Cantor Fitzgerald

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports. They presently have a $20.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 49.25% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Truist Financial initiated coverage on Y-mAbs Therapeutics in a report on Friday, June 28th. They set a “buy” rating and a $21.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Moderate Buy” and an average price target of $21.14.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock opened at $13.40 on Monday. The company has a market capitalization of $597.24 million, a P/E ratio of -27.35 and a beta of 0.70. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The stock has a 50-day simple moving average of $12.54 and a 200-day simple moving average of $13.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The firm had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period last year, the firm earned ($0.14) EPS. As a group, analysts forecast that Y-mAbs Therapeutics will post -0.57 earnings per share for the current year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at approximately $449,514. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 21.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of YMAB. Campbell & CO Investment Adviser LLC acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth $562,000. China Universal Asset Management Co. Ltd. boosted its holdings in Y-mAbs Therapeutics by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock worth $136,000 after buying an additional 3,340 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD grew its position in Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after buying an additional 1,657 shares during the period. Finally, Caxton Associates LP purchased a new position in Y-mAbs Therapeutics in the first quarter valued at about $306,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.